Baxalta and Precision BioSciences have entered a global collaboration to develop a series of allogeneic chimeric antigen receptor (CAR) T cell therapies directed towards areas of major unmet need in multiple cancers. The companies will develop CAR T therapies for as many as six unique targets, with the first program expected to enter trials in late 2017. Precision BioSciences will be responsible for early-stage research activities up to Phase II, after which Baxalta has the exclusive right to...